Nazione: Irlanda
Lingua: inglese
Fonte: HPRA (Health Products Regulatory Authority)
ALDIOXA
Stiefel Laboratories (U.K.) Ltd.
0.20 %w/w
Cutaneous Powder
1984-10-01
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Driclor Powder 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Aldioxa 0.20 % w/w. For excipients, see 6.1. 3 PHARMACEUTICAL FORM Cutaneous powder An off-white, absorbent, light free flowing cutaneous powder with a slight odour. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Driclor Powder is indicated in the management of intertrigo, hyperhidrosis and bromidrosis and in the prevention of Tinea pedis and related conditions. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The affected area should be dried as thoroughly as possible before applying Driclor Powder. Driclor Powder should be smoothed over the surface of the skin, between joints and folds. 4.3 CONTRAINDICATIONS Known hypersensitivity to the ingredients. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE As with all powders, care should be taken to avoid inhalation. 4.5 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION None. 4.6 PREGNANCY AND LACTATION There are no restrictions on the use of Driclor Powder in pregnancy and lactation. 4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES None. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 07/12/2006_ _CRN 2030889_ _page number: 1_ 4.8 UNDESIRABLE EFFECTS None. 4.9 OVERDOSE Not applicable. 5 PHARMACOLOGICAL PROPERTIES 5.1 PHARMACODYNAMIC PROPERTIES Driclor Powder contains aluminium dihydroxyallantoinate. Aluminium exerts a bacteriostatic action while allantoin promotes phagocytosis. Allantoin also acts as a hydrogen bond breaker, reducing hyperkeratinisation by its action on the intercellular cement. The leucocytic stimulant effects of allantoin cause debridement of necrotic tissue and generation of new tissue. The anti-irrit Leggi il documento completo